Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.52 (market cap $21.65M), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: Inovio Pharmaceuticals Inc is far larger — about 4.4× Avalanche Treasury Corporation Class A Common Stock's market cap. Which is the better fit depends on your goals.
| AVAT | INO | |
|---|---|---|
Market Cap | $21.65M | $95.85M |
Sector | Financials | Health |
52-Week High | $10.75 | $2.87 |
52-Week Low | $0.51 | $1.05 |
Enterprise Value | $21.65M | $66.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT stock trades at $0.506, down 6.3% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a low P/E of 12 and P/B of 0.4, but negative cash flow from operations at -$930,710 in 2025. Recent Nasdaq listing news highlights its role as an operating company and digital asset treasury focused on capital allocation across the Avalanche economy.
The outlook remains cautious due to negative operational cash flow and bearish technical indicators. Investment opportunity lies in the discounted valuation multiples, while risks include sustained cash burn and competitive pressures in treasury management services. Market sentiment is neutral with recent media coverage of the Nasdaq debut.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
